ZARAGOZA,
Spain and FRANKLIN LAKES, N.J., Oct. 21, 2020 /PRNewswire/ -- CerTest
Biotec, along with BD (Becton, Dickinson and Company) (NYSE: BDX),
a leading global medical technology company, today announced
that the VIASURE SARS-CoV-2 (N1 + N2) Real Time PCR
Detection Kit adapted for the BD MAX™ System has been CE
marked* to the IVD Directive (98/79/EC).
This kit allows BD MAX™ System users to run a single module that
tests concurrently for COVID-19 and Influenza (Flu) and Respiratory
Syncytial Virus (RSV).
"The new CerTest kit will provide rapid COVID-19 diagnostic
capabilities that can be run individually or combined with
detection of Flu A, Flu B and RSV A and B," said Nelson Fernandes, managing director of CerTest
Biotec. "As we enter flu season, the ability to test for both
COVID-19 and Flu at the same time will speed diagnosis and,
ultimately, treatment."
The BD MAX™ System, a molecular diagnostic platform, is widely
used in hundreds of laboratories across Europe. Each unit can return results in two to
three hours and is capable of analyzing hundreds of samples over a
24-hour period.
"Together with CerTest, we can offer our customers in
Europe a complete solution for
COVID-19 diagnostics during the winter season," said Nikos Pavlidis, vice president of Molecular
Diagnostics and Women's Health for BD. "By leveraging our
significant installed base and the versatility of the BD MAX
System, this test will greatly enhance capacity for SARS-CoV-2 and
Influenza testing, enabling clinicians to rapidly diagnose patients
and help reduce the spread of COVID-19."
The CerTest tests snaps into the test-specific position on the
BD MAX™ ExK™ TNA extraction strip, supplied by BD.
VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit
for the BD MAX™ System and the VIASURE Flu A, Flu B & RSV Real
Time PCR Detection Kit for the BD MAX™ System are sold through BD's
network and are not available for sale in the United States. To locate an authorized BD
representative or request information, visit: www.bd.com or
www.certest.es
* VIASURE Kits are not available for sale in the U.S.
Product availability may differ in different countries, please
contact your local BD representative.
About CerTest
CerTest Biotec is a European
company established in 2002 for the development and manufacturing
of in vitro diagnostic medical devices.
Today, CerTest is a global company structured around
5 business units offering one of the widest portfolios for human In
Vitro Diagnostic. The company bases its future on a strong
technical knowledge and expertise in the detection of human
diseases.
CerTest last generation laboratories,
state-of-the-art technical equipment and skilled professionals are
the keys for providing reliable solutions for the medical
diagnostic professional.
About BD
BD is one of the largest global medical
technology companies in the world and is advancing the world of
health by improving medical discovery, diagnostics and the delivery
of care. The company supports the heroes on the frontlines of
health care by developing innovative technology, services and
solutions that help advance both clinical therapy for patients and
clinical process for health care providers. BD and its 65,000
employees have a passion and commitment to help enhance the safety
and efficiency of clinicians' care delivery process, enable
laboratory scientists to accurately detect disease and advance
researchers' capabilities to develop the next generation of
diagnostics and therapeutics. BD has a presence in virtually every
country and partners with organizations around the world to address
some of the most challenging global health issues. By working in
close collaboration with customers, BD can help enhance outcomes,
lower costs, increase efficiencies, improve safety and expand
access to health care. For more information on BD, please
visit bd.com.
*BD and BD MAX trademarks are property of BD (Becton, Dickinson
and Company).
*VIASURE is a registered trademark of CerTest Biotec,
S.L.
Contacts:
|
|
|
|
Nelson
Fernandes,
|
|
CerTest Biotec
Managing Director
|
|
(+34) 976 520
354
|
|
nfernandes@certest.es
|
|
|
|
Kristen
Cardillo
|
Kristen M. Stewart,
CFA
|
BD Corporate
Communications
|
BD Investor
Relations
|
201-847-5657
|
201-847-5378
|
kristen.cardillo@bd.com
|
kristen.stewart@bd.com
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/certest-biotec-and-bd-announce-ce-mark-for-combination-covid-19-influenza-rsv-test-on-bd-max-molecular-diagnostic-system-301156403.html
SOURCE BD (Becton, Dickinson and Company)